Results 251 to 260 of about 1,636,249 (373)
Current status of liver transplantation (Editorial) [PDF]
Koep, LJ, Putnam, CW, Starzl, TE
core
This study identifies SPTAN1‐kla as a novel oncogenic driver in HBV‐driven HCC, linking metabolic, epigenetic, and immune mechanisms. SPTAN1‐kla promotes HCC progression via NOTCH1/HES1 activation and immunosuppression. Findings highlight that targeting SPTAN1‐kla provides a framework for HCC treatment to improve clinical outcomes in HBV infected ...
Zengbin Wang +8 more
wiley +1 more source
Rare case of triple kidney with horseshoe fusion. [PDF]
El Aouadi S +7 more
europepmc +1 more source
ACTIVE OBSERVATION TACTICS IN PATIENTS WITH KIDNEY NEOPLASMS
B. Yа. Alekseev, А. S. Kalpinskiy
openalex +2 more sources
This study demonstrates that Mn2⁺–tumor DNA complexes encapsulated in dendritic cell (DC)– derived immunogenic extracellular vesicles (EVDC@Mn‐DNA) act as a DC‐specific cGAS– STING activator. EVDC@Mn‐DNA treatment enhances intratumoral DC activation, improves tumor vascular function, promotes CD8⁺ T cell activity, and suppresses pancreatic tumor growth,
Xue Jiang +13 more
wiley +1 more source
Renal oncocytomatosis: A rare case of bilateral multifocal oncocytomas 15 Years after solitary lesion: a case report. [PDF]
Rosario M, Sitharthan D, Sved P.
europepmc +1 more source
PDAC has a poor prognosis due to chemoresistance. We revealed that MCU upregulation is associated with chemoresistance and stemness in PDAC. MCU‐mediated Ca2+ influx induced ER stress, activating the PERK‐ATF4/NRF2 axis to enhance PSAT1/SLC711 expression and glutathione synthesis, reducing ROS and maintaining stemness.
Zekun Li +17 more
wiley +1 more source
<i>De novo</i> malignancy development following kidney transplantation: Managing risks and outcomes in clinical practice. [PDF]
Huseynov A, Kuşlu Çiçek SN.
europepmc +1 more source

